Prime Minister Justin Trudeau says Canada has been warned of manufacturing problems plaguing the Johnson & Johnson vaccine.
The viral vector vaccine developed by J&J’s subsidiary, Janssen Pharmaceuticals, was authorized by Health Canada as safe and effective last week.
Canada pre-ordered 10 million doses of the vaccine, which is the first and only one in Canada’s vaccine plan that needs only one dose.
But Trudeau says Canada still doesn’t have a date for when it should receive the first deliveries.
“We have heard in many conversations with Johnson & Johnson that there are challenges around production of the Janssen vaccine, but we will continue to engage with them and we look forward to receiving doses as soon as possible,” he said Tuesday at a news conference in Ottawa.
Canada pre-purchased millions of doses of seven different vaccine types, and Health Canada has approved four so far for the various provincial and territorial rollouts. All the drugs are fully effective in preventing serious illness and death, though some may do more than others to stop any symptomatic illness at all (which is where the efficacy rates cited below come in).
- Also known as: Comirnaty
- Approved on: Dec. 9, 2020
- Efficacy rate: 95 per cent with both doses in patients 16 and older, and 100 per cent in 12- to 15-year-olds
- Traits: Must be stored at -70 C, requiring specialized ultracold freezers. It is a new type of mRNA-based vaccine that gives the body a sample of the virus’s DNA to teach immune systems how to fight it. Health Canada has authorized it for use in people as young as 12.
- Also known as: SpikeVax
- Approved on: Dec. 23, 2020
- Efficacy rate: 94 per cent with both doses in patients 18 and older, and 100 per cent in 12- to 17-year-olds
- Traits: Like Pfizer’s vaccine, this one is mRNA-based, but it can be stored at -20 C. It’s approved for use in Canada for ages 12 and up.
- Also known as: Vaxzevria
- Approved on: Feb. 26, 2021
- Efficacy rate: 62 per cent two weeks after the second dose
- Traits: This comes in two versions approved for Canadian use, the kind made in Europe and the same drug made by a different process in India (where it is called Covishield). The National Advisory Committee on Immunization’s latest guidance is that its okay for people 30 and older to get it if they can’t or don’t want to wait for an mRNA vaccine, but to guard against the risk of a rare blood-clotting disorder, all provinces have stopped giving first doses of AstraZeneca.
- Also known as: Janssen
- Approved on: March 5, 2021
- Efficacy rate: 66 per cent two weeks after the single dose
- Traits: Unlike the other vaccines, this one comes in a single injection. NACI says it should be offered to Canadians 30 and older, but Health Canada paused distribution of the drug for now as it investigates inspection concerns at a Maryland facility where the active ingredient was made.
How many vaccine doses do I get?
All vaccines except Johnson & Johnson’s require two doses, though even for double-dose drugs, research suggests the first shots may give fairly strong protection. This has led health agencies to focus on getting first shots to as many people as possible, then delaying boosters by up to four months. To see how many doses your province or territory has administered so far, check our vaccine tracker for the latest numbers.
“And as soon as we get confirmation of doses being sent to Canada, we will let everyone know.”
Canada’s vaccine rollout has stepped up this month, after deliveries slowed to a trickle in February. Nearly a million doses of Pfizer-BioNTech and Oxford-AstraZeneca vaccines were delivered last week, and 910,000 doses of Pfizer’s and Moderna’s vaccines are arriving this week.
It took Canada 67 days to vaccinate the first one million people. It should take less than one-third that time to vaccinate the second million.
As of Tuesday, more than 1.9 million Canadians had received at least one dose.
Chief public health officer Dr. Theresa Tam said Canada isn’t quite ready to follow the U.S. Centers for Disease Control with guidance for how vaccinated people can relax their public health measures.
The CDC said Monday that two weeks after getting their second doses, Americans can now visit indoors, without masks, with other fully vaccinated people, or those who are not vaccinated but are at low risk of serious illness.
Tam said there are still too many unknowns, including the effect of COVID-19 variants, and how vaccines will affect the spread of the novel coronavirus.
The United States is far ahead of Canada, having now vaccinated more than one in four people. Canada has vaccinated about one in 20.
Tam said there are “initial positive signs” that the Pfizer and Moderna vaccines are preventing transmission, as well as reducing the severity of illness, but it is still early.
The emergence of variants that aren’t all responding as well to vaccines is also of concern, she said. Tam said Ontario now believes almost one-third of its new cases are one of those variants, with the B.1.1.7 variant first identified in the United Kingdom the most common.
That variant also appears to be the most receptive to the current vaccines.
Manitoba said Tuesday it had confirmed five new cases of B.1.1.7 and eight of another variant called B.1.351, but also said there did not appear to be any community transmission.
Saskatchewan said it had 35 new cases of variants among cases testing positive between Jan. 26 and Feb. 27, almost all of them B.1.1.7.
Alberta, meanwhile, said it had 28 new variant cases, for a total of 687.
B.C. had another 182 variant cases for a total of 576, most of them linked to the strain first found in the United Kingdom.
Tam said the next couple of weeks will be critical as many provinces have just begun easing the tightest lockdowns this week.
“We will know pretty soon, I think, as to whether we are able to keep the variants at manageable proportions while vaccines are escalated,” Tam said. “Which is why now is not the time to sort of make too many shifts in the public health measures at this time. But we will be able to do so based on what actually happens next.”
Ontario moved COVID-19 hot zones of Toronto and Peel out of total lockdown Monday, allowing retail stores to admit customers for the first time in 100 days, but is keeping restaurants closed to in-person dining. Quebec adjusted restrictions in five regions, including Quebec City, allowing gyms and restaurants to reopen in limited capacity for the first time since before Christmas.
Saskatchewan said Tuesday it was immediately ending its total ban on household gatherings, allowing people to have up to 10 people over from two or three different households. Next week it will increase capacity limits on houses of worship.
The number of new cases in Canada has plateaued at about 2,900 cases per day for about three weeks, but since Feb. 23, the average number of deaths per day has fallen from 54 to 37.
Newfoundland and Labrador also seems to be recovering from a major outbreak that swept through St. John’s last month. Public health officials reported one new case Tuesday and said active infections are down to 80, from 203 a week ago.
Canada’s vaccine contracts set out expected deliveries by quarter and all 10 million of Canada’s J&J doses are to come between April and September. But it’s not yet known how many are to come in the spring and how many in the summer.
Johnson & Johnson production problems are affecting Europe and the U.S. as well. Several European countries, where the vaccine isn’t yet authorized, said they don’t expect as many doses of it next month as originally planned.
U.S. President Joe Biden said last week when he took office he was informed Johnson & Johnson was behind on production and efforts began to find more production space. Sanofi was first contracted to help produce the vaccine in Europe and last week Biden announced Merck would help produce it in the United States.
But it will be many months before they have production lines up and running.
The Canadian Press
Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.